Granules India Limited

GRANULES

INE101D01020

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:56 2024-06-03 am EDT			5-day change	1st Jan Change
441 ^INR	+5.45%		+2.79%	+8.77%

May. 15	Transcript : Granules India Limited, Q4 2024 Earnings Call, May 15, 2024
May. 15	Granules India Posts Decline in Fiscal Q4 Consolidated Net Profit, Revenue	MT

Granules India Limited Announces Resignation of C. Parthasarathy as Independent Director

December 26, 2019 at 03:37 am EST

Granules India Limited announced that Mr. C. Parthasarathy has resigned as Independent Director of the company and the board of directors has taken note of the same. His resignation is effect from December 26, 2019.

Latest news about Granules India Limited

Transcript : Granules India Limited, Q4 2024 Earnings Call, May 15, 2024	May. 15
Granules India Posts Decline in Fiscal Q4 Consolidated Net Profit, Revenue	May. 15	MT
Granules India posts Q4 revenue fall on weak paracetamol sales, price erosion	May. 15	RE
Granules India Limited Recommends Final Dividend for the Financial Year 2023-24, Payable on July 30, 2024	May. 15	CI
Granules India Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	May. 15	CI
Granules India Limited Reports Earnings Results for the Full Year Ended March 31, 2024	May. 15	CI
Granules Pharmaceuticals Arm Gets US FDA's Approval for Generic Drug for Gout Flares	Apr. 30	MT
Granules India Gets Zero Observation from US FDA After Inspection of Visakhapatnam, India Unit	Apr. 15	MT
Granules India Unit Gets VAI Status for Virginia Facility	Apr. 03	MT
Granules India Limited Announces Appointment of Directors	Apr. 02	CI
Granules India Limited Announces Cessation of Arun Rao Akinepally as Independent Director	Mar. 29	CI
Granules India Limited Announces Appointment of Sethu Madhavan Sankaran as Senior Vice President - Api Manufacturing & Operations	Mar. 29	CI
Granules India Limited Appoints Atul Dhavle as Chief Human Resources Officer	Mar. 11	CI
Granules India Limited Announces That J. Shravan Reddy Shall Cease to Be Senior Vice President & Head- API Manufacturing	Mar. 05	CI
Transcript : Granules India Limited, Q3 2024 Earnings Call, Jan 23, 2024	Jan. 23
Paracetamol maker Granules India posts marginal rise in Q3 profit	Jan. 23	RE
Granules India's Posts Gains in Fiscal Q3 Consolidated Net Profit	Jan. 23	MT
Granules India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Jan. 23	CI
Granules Pharmaceuticals Unit's Virginia Facility Gets Five Observations from US FDA	Dec. 18	MT
Granules India Gets US FDA Nod for Pantoprazole Sodium Delayed-Release Tablets	Dec. 13	MT
Granules India Limited Receives ANDA Approval for Pantoprazole Sodium Delayed-Release Tablets	Dec. 13	CI
Granules India Arm Gets US FDA Nod for Sildenafil for Oral Suspension	Dec. 03	MT
Paracetamol maker Granules India's Q2 revenue rises on higher N.America demand	Nov. 09	RE
Transcript : Granules India Limited, Q2 2024 Earnings Call, Nov 09, 2023	Nov. 09
Granules India Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 09	CI

Chart Granules India Limited

Duration

Period

More charts

Company Profile

Granules India Limited is an India-based pharmaceutical manufacturing company. The Company operates through its pharmaceuticals products segment. Its geographical segments include within India and outside India. The Company has its presence across the pharmaceutical manufacturing value chain, including active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediaries (PFIs) and finished dosages (FDs). It has over eight manufacturing facilities, approximately seven of which are located in India and one in the United States. The Company sells its products in the global markets, including the United States of America, Canada, Latin America, Europe, Asia Pacific and India. The Companyâs wholly owned subsidiaries include Granules USA Inc, Granules Pharmaceuticals Inc, Granules Europe Limited and Granules Lifesciences Private Limited.

Sector

Pharmaceuticals

Calendar

2024-07-29 - Ex-dividend day for final dividend

More about the company

Income Statement Evolution

More financial data

Ratings for Granules India Limited

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

441 INR

Average target price

473 INR

Spread / Average Target

+7.27%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GRANULES INDIA LIMITED	+8.77%	1.21B
ELI LILLY AND COMPANY	+42.64%	739B
NOVO NORDISK A/S	+32.34%	598B
JOHNSON & JOHNSON	-5.73%	353B
MERCK & CO., INC.	+17.33%	318B
ABBVIE INC.	+3.44%	285B
ASTRAZENECA PLC	+16.47%	240B
NOVARTIS AG	+9.26%	210B
ROCHE HOLDING AG	-5.07%	206B
AMGEN INC.	+6.09%	164B

Other Pharmaceuticals